Semaglutide: tested in a combination

116 studies: another drug in the study is under test too. Page 1 of 2. Open to participants first (67), then studies with results posted, then the rest; newest registration first within each.

• Safety and Pharmacokinetics of UI112 Compared With UIC202611 in Healthy AdultsNot yet recruitingNCT07935200Phase 1Report a problem
• Mechanisms of Weight Loss: Tirzepatide vs SemaglutideRecruitingNCT07900074Phase 4Report a problem
• Dietary, Medication, and Endoscopic Interventions for Post-Bariatric HypoglycemiaNot yet recruitingNCT07878494Not applicableReport a problem
• Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1sNot yet recruitingNCT07832084Phase 4Report a problem
• A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or ObesityNot yet recruitingNCT07783854Phase 4Report a problem
• Semaglutide in Youth With Autism Spectrum DisorderRecruitingNCT07770152Phase 4Report a problem
• GLP-1s in Hip and Knee ArthroplastyNot yet recruitingNCT07755085Phase 4Report a problem
• Tirzepatide Impact Assessment StudyRecruitingNCT07740291Not applicableReport a problem
• Bariatric Surgery Combined With GLP-1RA: A Multicenter Study.RecruitingNCT07732738Not applicableReport a problem
• Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese ParticipantsRecruitingNCT07673900Phase 1Report a problem
• Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's DiseaseRecruitingNCT07651319Phase 1/2Report a problem
• GLP-1 Therapy After Bariatric Surgery in Chinese Patients With ObesityRecruitingNCT07633639Not applicableReport a problem
• SHIELD-T1D: Shingrix and GLP-1 Agonist for Beta-Cell Preservation in Recent-Onset Type 1 Diabetes.Not yet recruitingNCT07614412Phase 2Report a problem
• Comparative Observation of Metabolic and Pharmacologic Adipose Remodeling With Enhanced Incretin AgonisTsRecruitingNCT07589322Not applicableReport a problem
• Safety, Tolerability and Efficacy of Semaglutide Depot in Subjects With Type-2 Diabetes MellitusRecruitingNCT07563699Phase 1/2Report a problem
• Effect of GLP-1RA on Cardiac Autonomic Neuropathy in Type 2 DiabetesRecruitingNCT07558863Phase 4Report a problem
• Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)Enrolling by invitationNCT07547878Phase 4Report a problem
• A Phase 1 Clinical Trial to Assess the Safety of DWRX5003 and Relative Bioavailability to DWC202502 and DWC202503 in Healthy Adult VolunteersRecruitingNCT07539415Phase 1Report a problem
• Low-Dose Semaglutide for Weight Loss in Obese Non-Diabetic Pakistani AdultsRecruitingNCT07513168Phase 4Report a problem
• Semaglutide for Treatment of People With Methamphetamine Use Disorder: the SHIFT StudyNot yet recruitingNCT07509112Phase 2Report a problem
• DECODE - Haemodynamic Effects Of Semaglutide and Tirzepatide - a Series of Pilot StudiesNot yet recruitingNCT07483801Phase 4Report a problem
• Reversal to Normoglycemia by Treating PrediabetesNot yet recruitingNCT07392151Phase 3Report a problem
• Bariatric Surgery Combined With GLP-1 Receptor Agonists StudyRecruitingNCT07336862Phase 1/2Report a problem
• Incretin Microdosing for Cardiometabolic Health in People With HIVRecruitingNCT07325500Phase 2Report a problem
• Effect of Semaglutide and Tirzepatide Combined With Exercise in ObesityNot yet recruitingNCT07319975Not applicableReport a problem
• Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide TerminationRecruitingNCT07294950Phase 3Report a problem
• Semaglutide and Tirzepatide for Genetic Aging Delay in Adults With ObesityRecruitingNCT07293325Not applicableReport a problem
• Anti-atherosclerotic Efficacy of Selected Antidiabetic Drugs in Patients With Coronary Artery Disease and Pre-diabetesRecruitingNCT07254572Phase 4Report a problem
• Combination Therapy for Alcohol Use DisorderNot yet recruitingNCT07249554Phase 2Report a problem
• Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)RecruitingNCT07225816Phase 1Report a problem
• Individualized Pharmacological Approach to Obesity in Patients With Bipolar DisorderRecruitingNCT07213466Phase 4Report a problem
• Metabolic Interventions (Time-Restricted Eating, GLP1 Receptor Agonist, and Heart Healthy Diet) to Improve Cardiometabolic Health in Prostate Cancer Patients During Androgen Deprivation Therapy, IMPACT-ADT TrialRecruitingNCT07202247Phase 2Report a problem
• Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm HealthNot yet recruitingNCT07179120Phase 2Report a problem
• The Effect of Semaglutide on Bone HealthNot yet recruitingNCT07165158Phase 4Report a problem
• A Study to Estimate Early Clinical Efficacy Signals of GLP-1 Agonist Administration in Conjunction With Levonorgestrel Intrauterine Device in Obese Patients With Endometrioid Intraepithelial NeoplasiaRecruitingNCT07107334Phase 2Report a problem
• Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity MeasuresEnrolling by invitationNCT07092605Early Phase 1Report a problem
• Aging Well: Targeting Obesity With GLP-1 Agonists to Enhance Physical and Vascular Health in Postmenopausal WomenEnrolling by invitationNCT07057310Phase 4Report a problem
• Phase III Clinical Study on the Efficacy and Safety of Semaglutide and Ozempic® in Patients With Type 2 DiabetesNot yet recruitingNCT07046273Phase 3Report a problem
• Efficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese PatientsRecruitingNCT07036172Phase 3Report a problem
• Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance DialysisRecruitingNCT07017270Phase 4Report a problem
• Focusing on the Menopausal Transition to Improve Mid-Life Women's HealthRecruitingNCT06975111Phase 2/3Report a problem
• Urinary Proteomics to Guide Early Intervention to Prevent Complications in Type 2 Diabetes - a Feasibility StudyEnrolling by invitationNCT06954090Phase 4Report a problem
• New Triple Therapy in Newly Diagnosed Type 2 DiabetesNot yet recruitingNCT06946628Phase 3Report a problem
• Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes PatientsEnrolling by invitationNCT06924697Not applicableReport a problem
• Bone Metabolism in 12-21 Year Olds Undergoing Glucagon Like Peptide (GLP)-1 Receptor Agonist TherapyRecruitingNCT06903923Phase 2Report a problem
• A Clinical Trial to Evaluate The Effects of Semaglutide and Empagliflozin Combined to Automated Insulin Delivery on Diabetes Control in Adults Living With Type 1 DiabetesRecruitingNCT06894784Phase 3Report a problem
• Efficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes MellitusNot yet recruitingNCT06616961Phase 3Report a problem
• Effect of Early Combination Antihyperglycemic Treatment on Metabolic Control in Individuals With Type 2 DiabetesRecruitingNCT06613854Phase 4Report a problem
• Physiologic Response to Bariatric Surgery and the Impact of Adjunct Semaglutide in AdolescentsRecruitingNCT06575738Phase 1Report a problem
• Prevention of Progression of Prediabetes, Obesity and CV RiskRecruitingNCT06446531Phase 1Report a problem
• A Study to Evaluate Safety, Tolerability and pK of Semaglutide ER Injectable Suspension in Healthy, Adult Human SubjectsNot yet recruitingNCT06422624Phase 1Report a problem
• Alleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous SemaglutideRecruitingNCT06387199Phase 2/3Report a problem
• Impact GLP-1 Agonists Following BariatricRecruitingNCT06132477Phase 4Report a problem
• Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 DiabetesRecruitingNCT06082063Phase 3Report a problem
• Weight-loss Drug for Fertility-Sparing Treatment of Atypical Hyperplasia and Low-grade Cancer of the EndometriumRecruitingNCT06073184Phase 2Report a problem
• COMMETS- Combination MCI Metabolic SyndromeRecruitingNCT06072963Phase 2Report a problem
• Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes MellitusRecruitingNCT06060392Not applicableReport a problem
• The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic EffectRecruitingNCT06058585Phase 3Report a problem
• Therapeutic Effects and Effects on Body Fat of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes for 1-4 YearsRecruitingNCT05990374Not applicableReport a problem
• The Efficacy, Mechanism & Safety of Sodium Glucose Co-Transporter-2 Inhibitor & Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Kidney Transplant RecipientsRecruitingNCT05938712Phase 2Report a problem
• Effects of GLP-1RA on Body Weight, Metabolism and Fat Distribution in Overweight/Obese Patients With Type 2 Diabetes MellitusRecruitingNCT05779644Not applicableReport a problem
• Effect on Non-Alcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus With Gastric Inhibitory Polypeptide/Glucagon Like Peptide-1 AnalogueRecruitingNCT05751720Phase 1/2Report a problem
• Sex Steroids Balance for Metabolic and Reproductive Health in Klinefelter SyndromeRecruitingNCT05586802Phase 3Report a problem
• Adipose Tissue Heterogeneity and Its Link to Type 2 DiabetesRecruitingNCT05501483Not applicableReport a problem
• PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 DiabetesRecruitingNCT05390892Phase 4Report a problem
• GLP-1 Analogue in Preventing Progression of Small Vessel Disease (GAPP-SVD)RecruitingNCT05356104Phase 2Report a problem
• Effect of Weekly GLP1 Agonist Treatment in "Double Diabetes"RecruitingNCT05305794Phase 3Report a problem
• Holding vs. Continuing Incretin-based Therapies Before Upper EndoscopyCompletedNCT06533527Phase 4Results postedReport a problem
• A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 DiabetesCompletedNCT05813912Phase 3Results postedReport a problem
• A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin IcodecCompletedNCT05352815Phase 3Results postedReport a problem
• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)CompletedNCT04971785Phase 2Results postedReport a problem
• Lifestyle Counseling and Medication for Adolescent Weight ManagementCompletedNCT04873245Phase 2Results postedReport a problem
• A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and LiraglutideCompletedNCT00696657Phase 2Results postedReport a problem
• ELITE: Deep Profiling and Algorithmic Polytherapy to Map Individual Response in Healthy AgingCompletedNCT07871799Phase 2Report a problem
• Weekly GLP-1 Receptor Agonists in Obese Individuals Without DiabetesCompletedNCT07834398Phase 3Report a problem
• Comparative Study of Different Weekly GLP-1 Receptor Agonists Among Diabetic and Non-Diabetic Patients: Clinical TrialCompletedNCT07820111Phase 3Report a problem
• Optimizing Albuminuria Treatment in CKD With Finerenone and SemaglutideCompletedNCT07819227Phase 2Report a problem
• Adiponectin in Patients With Metabolic DisordersCompletedNCT07539584Not applicableReport a problem
• Beta Cell Function in Type 2 Diabetes: Differential Effects of SGLT2 Inhibitors and GLIP-Receptor AgonistsActive, not recruitingNCT07325435Phase 4Report a problem
• Effect of GLP-1 on Intestinal Barrier Function in SBS-IF Patients: A Preliminary Exploration.CompletedNCT07297238Not applicableReport a problem
• Semaglutide in Women With Polycystic Ovary Syndrome and ObesityCompletedNCT06896981Phase 2/3Report a problem
• Sequential Therapy Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)Active, not recruitingNCT06854614Phase 4Report a problem
• Optimization of Obesity for Total Knee Replacement With Glucagon-like Peptide-1 Receptor AgonistActive, not recruitingNCT06807970Early Phase 1Report a problem
• Bariatric Surgery vs. Semaglutide vs. TirzepatideActive, not recruitingNCT06803888Phase 4Report a problem
• Effects of Long-Acting GLP-1 (Glucagon-like Peptide-1) or Dual Incretin (GLP-1 and GIP [Glucose-dependent Insulinotropic Peptide]) Modulation on Gastric Motor FunctionsActive, not recruitingNCT06801015Phase 4Report a problem
• Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 DiabetesCompletedNCT06762314Phase 2Report a problem
• Evaluating the Effect of the STEP@STAH Semaglutide Protocol on the Physical Health Measures of Atypical Antipsychotic-Treated PatientsActive, not recruitingNCT06754163Phase 4Report a problem
• Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 DiabetesCompletedNCT06739044Phase 3Report a problem
• Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose HomeostasisActive, not recruitingNCT06715514Not applicableReport a problem
• Comparison of the Safety, Efficacy and Pharmacokinetics of DehydraTECH -CBD and DehydraTECH-GLP1 Agonists Alone or in Combination, in Overweight or Obese, Pre- and Type 2 Diabetic ParticipantsCompletedNCT06648031Phase 1Report a problem
• A Research Study Looking at New Protein-based Tablets in Healthy Men - Oral Formulation IVCompletedNCT06642584Phase 1Report a problem
• Pharmacokinetic Similarity, Safety, and Immunogenicity of Semaglutide Injection and Ozempic ® Injection in Healthy Subjects.CompletedNCT06634927Phase 1Report a problem
• Semaglutide in Treatment of ObesityCompletedNCT06604624Phase 3Report a problem
• Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver DiseaseCompletedNCT06409130Phase 2Report a problem
• Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney DiseaseStatus unknownNCT06344247Not applicableReport a problem
• A Study of How CagriSema Works on Appetite in People With Excess Body WeightCompletedNCT06267092Phase 1Report a problem
• Novel Therapeutics and Endothelial Dysfunction in T1DM PatientsCompletedNCT05857085Phase 4Report a problem
• Semaglutide in Nonalcoholic Fatty Liver DiseaseCompletedNCT05813249Phase 4Report a problem
• A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy ParticipantsCompletedNCT05784402Phase 1Report a problem
• A Research Trial Looking at the Comparability of 2 Different Concentrations of Semaglutide for the 0.5 Milligram (mg) DoseCompletedNCT05689099Phase 1Report a problem

← Semaglutide